Syndicate Invests $26.7m in Microbiome Therapeutics Company BiomX

d6a63e0b-d311-453c-85c2-358358fd8a1farticleimage.jpg

19 May 2017 --- A global syndicate which includes corporate venture funds Seventure Partners, Takeda Ventures and Johnson and Johnson Development Corporation has announced a $26.7 million (€24 million) investment in Israeli microbiome therapeutics company BiomX. 

BiomX focuses on developing novel therapeutics to alleviate human diseases stemming from dysbiosis of the microbiome. Its initial product candidates are based on bacteriophages (viruses which target and kill specific species or strains of bacteria). The company also uses unique technologies to identify microbiome targets for key diseases. 

The investment will be used for further developing BiomX’s drug candidate and obtain clinical proof of concept for the lead compound enabling the company to develop its world-leading IP and position itself as a major player in developing prescription-drug (Rx) therapeutics using scientific insights from its microbiome research.

“Since the beginning of the 20th Century, bacteriophage therapy has fascinated scientists by its ability to kill bacteria specifically and efficiently. But it lost out to antibiotics as a weapon against infectious diseases. BiomX is innovating by reviving this technology in the context of rebalancing the human microbiome to fight against chronic diseases,” says Eric de La Fortelle, Venture Partner at Seventure Partners.

Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners, comments: “The microbiome field has is complex with multiple approaches having synergistic roles in healthcare. BiomX’s approach using bacteriophage seeks to harness natural mechanisms to restore a healthy microbiome balance to the gut. Israel is widely recognized for its expertise and innovation in life sciences, and our investment in a new region reflects how we are expanding our investment horizons internationally.”

Related Articles

Business News

BASF: “considerable” Q2 earnings growth, but Nutrition & Health sales stall

27 Jul 2017 --- BASF Group has announced that its second quarter sales rose by 12 percent to €16.3 billion (US$19.11 billion) compared with the same period in 2016. The group states that this was largely attributable to higher prices and volumes. Amid higher raw material costs, the company raised sales prices by 7 percent; this was mainly driven by higher prices in the Chemicals segment. Sales volumes increased by 3 percent. Currency effects had a positive impact on sales and, like portfolio effects, accounted for a 1 percent increase.

Regulatory News

Cargill’s erythritol dental health claim rejected by EFSA

27 Jul 2017 --- Cargill cannot prove its EU Article 14 claim submission [disease risk reduction claim] that there is a cause-and-effect relationship between sugar-free hard confectionery with at least 90 percent erythritol and the reduction of dental plaque, according to the European Food Safety Authority (EFSA).

Business News

Algatech eyes Brazil market following Anvisa approval for astaxanthin line

27 Jul 2017 --- Algatechnologies has received Brazilian Health Regulatory Agency (Anvisa) approval for its all-natural astaxanthin AstaPure to be used as a food ingredient. This approval makes Algatech the first astaxanthin supplier to start marketing its clean-label astaxanthin under the AstaPure brand in Brazil. 

Nutrition & Health News

Binge drinking among young US adults not in college increased

27 July 2017 --- Binge drinking rates are finally down among US college students aged 18 to 24, after years of increases, but they are up among those in the same age group who are not in college, according to a study in the July issue of the Journal of Studies on Alcohol and Drugs. The same study also found that alcohol-related hospitalizations and overdose deaths have increased generally among 18- to 24-year-olds.

Business News

Food and health startups get chance to impress in Innovation Challenge

27 Jul 2017 --- Innovative ingredient projects, carried out by startups that have brought something completely new and unexpected to the food and health markets, will be rewarded as part of the Startup Innovation Challenge during the next Fi Europe & Ni show from November 28 to 30 this year.

More Articles
URL : http://www.nutritioninsight.com:80/news/syndicate-invests-267m-in-microbiome-therapeutics-company-biomx.html